Rodman & Renshaw Downgardes Bioenvision (BIVN) to Market Perform
BIVN Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Rodman & Renshaw downgardes Bioenvision (NASDAQ: BIVN) from Market Outperform to Market Perform. The analyst does not expect the stock price of Bioenvision (NASDAQ: BIVN) to increase due to the fact that the shareholders of Bioenvision are expected to accept the $345 million bid from Genzyme (NASDAQ: GENZ). The firm does not expect a higher bid.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- KeyBanc Downgrades Lululemon Athletica Inc. (LULU) to Hold; Valuation Call & Slight Concern of U.S. Slowdown
- JPMorgan Downgrades Heinz (HNZ) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
